Medication Use, Cormobidity and Outcomes in Aging Populations
Medication Use, Cormobidity and Outcomes in Aging Populations
批准号:
7609031
负责人:
Robert J Glynn
金额:
$32.29万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-05-15 至 2011-03-31
关键词:
AccountingAgeAgingAlgorithmsAnti-Inflammatory AgentsAnti-inflammatoryAsthmaBone ResorptionBritish ColumbiaCaringCessation of lifeChronicChronic DiseaseChronic Obstructive Airway DiseaseClinicalComorbidityComplexConsumptionContractsControl GroupsDataData AnalysesData SourcesDiagnosisDiseaseDrug PrescriptionsDrug usageElderlyEligibility DeterminationEvaluationFoundationsGlaucomaHospitalizationInterventionLifeLipidsLongitudinal StudiesMedication ManagementMethodsModificationMorbidity - disease rateObservational StudyOsteoporosisOutcomeOutpatientsPalliative CareParkinson DiseasePatientsPennsylvaniaPersonsPharmaceutical PreparationsPharmacotherapyPharmacy facilityPhysiciansPopulationPreventiveProcessProvinceRelative (related person)RiskRoleSeriesSymptomsTimeVisitWithholding TreatmentWomanactive controlagedbasecomparison groupdepressiondesignend of lifehigh riskimprovedinterestmortalityprogramspublic health relevancetherapy development
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): A panel of geriatric clinical experts rated problems in pharmacologic management as the most important target for improvement of care in vulnerable older people. People aged 65 years or older have the highest age- specific drug consumption rates, yet abundant evidence indicates that they commonly do not receive appropriate drug treatment for a wide variety of conditions. In particular, older persons with complex chronic diseases appear to have a reduced likelihood of receiving preventive drug treatment for unrelated diseases. This application aims to conduct large-scale, longitudinal, observational studies of determinants of initiation and persistence of use of preventive drugs in older people. A particular focus is on the impact of common, symptomatic conditions, including depression, Parkinson disease, and chronic obstructive lung disease, on use of preventive therapies, including glaucoma drugs, bone resorption agents, and lipid-lowering drugs. Another evaluation will consider the relative use of drugs in the last year of life. Additional methodological aims will quantify the clustering of drug use within prescribers and evaluate alternative reference groups for studies of new users of specific medication classes. Studies will utilize administrative claims data from two large populations of persons aged 65 years or older: 1) over 500,000 older residents of Pennsylvania who had prescription drug coverage through that state's Pharmacy Assistance Contract for the Elderly (PACE) program between the years 1994 and 2004; and 2) all residents of British Columbia, including over 500,000 persons during the years 1995-2005, who received prescription benefits through that province's Pharmacare program. Data sources for these populations include: drug claims for all filled prescriptions; data on hospitalizations and outpatient visits including diagnoses; demographic information on patients and their prescribers; and information on program eligibility and mortality. These populations include large numbers of persons at particular risk for under-treatment including those aged 85 and above, women, blacks and those with multiple morbidities. Data analysis will use methods for longitudinal and clustered data to account for repeat prescriptions in the same people and to characterize the clustering of patients within prescribers. These studies are intended to advance methodologic strategies for evaluation of drug use and its effects in older people and to lay the foundation for interventions to improve prescribing in this population. A panel of geriatric clinical experts rated problems in pharmacologic management as the most important target for improvement of care in vulnerable older people. The proposed studies will identify determinants of initiation and persistence in use of therapies of proven efficacy based on administrative claims data including information from large numbers of persons at particular risk for under-treatment such as those aged 85 years and above, women, blacks, and those with multiple morbidities. These studies are intended to advance methodologic strategies for evaluation of drug use and its effects in older people and to lay the foundation for interventions to improve prescribing in this population. PUBLIC HEALTH RELEVANCE: A panel of geriatric clinical experts rated problems in pharmacologic management as the most important target for improvement of care in vulnerable older people. The proposed studies will identify determinants of initiation and persistence in use of therapies of proven efficacy based on administrative claims data including information from large numbers of persons at particular risk for under-treatment such as those aged 85 years and above, women, blacks, and those with multiple morbidities. These studies are intended to advance methodologic strategies for evaluation of drug use and its effects in older people and to lay the foundation for interventions to improve prescribing in this population.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cardiovascular Inflammation Reduction Trial (CIRT): DCC
-
批准号:8039355
-
项目类别:
-
资助金额:$49.61万
-
财政年份:2011
-
负责人:Robert J Glynn
-
依托单位:
Cardiovascular Inflammation Reduction Trial (CIRT): DCC
-
批准号:8657091
-
项目类别:
-
资助金额:$141.2万
-
财政年份:2011
-
负责人:Robert J Glynn
-
依托单位:
Cardiovascular Inflammation Reduction Trial (CIRT): DCC
-
批准号:8463024
-
项目类别:
-
资助金额:$119.89万
-
财政年份:2011
-
负责人:Robert J Glynn
-
依托单位:
Cardiovascular Inflammation Reduction Trial (CIRT): DCC
-
批准号:8307698
-
项目类别:
-
资助金额:$65.0万
-
财政年份:2011
-
负责人:Robert J Glynn
-
依托单位:
Determinants of Venous Thromboembolism in Older People
-
批准号:7340270
-
项目类别:
-
资助金额:$22.68万
-
财政年份:2007
-
负责人:Robert J Glynn
-
依托单位:
Determinants of Venous Thromboembolism in Older People
-
批准号:7894557
-
项目类别:
-
资助金额:$22.0万
-
财政年份:2007
-
负责人:Robert J Glynn
-
依托单位:
Determinants of Venous Thromboembolism in Older People
-
批准号:7502144
-
项目类别:
-
资助金额:$22.23万
-
财政年份:2007
-
负责人:Robert J Glynn
-
依托单位:
Determinants of Venous Thromboembolism in Older People
-
批准号:7651196
-
项目类别:
-
资助金额:$22.23万
-
财政年份:2007
-
负责人:Robert J Glynn
-
依托单位:
Epidemiology of Venous Thromboembolism
-
批准号:6773942
-
项目类别:
-
资助金额:$31.5万
-
财政年份:2002
-
负责人:Robert J Glynn
-
依托单位:
Epidemiology of Venous Thromboembolism
-
批准号:6508692
-
项目类别:
-
资助金额:$31.56万
-
财政年份:2002
-
负责人:Robert J Glynn
-
依托单位:
Medication Use, Cormobidity and Outcomes in Aging Populations
-
批准号:7812090
-
项目类别:
-
资助金额:$31.96万
-
财政年份:2002
-
负责人:Robert J Glynn
-
依托单位:
Medication Use, Comorbidity and Outcomes in Older People
-
批准号:6624094
-
项目类别:
-
资助金额:$34.6万
-
财政年份:2002
-
负责人:Robert J Glynn
-
依托单位:
Epidemiology of Venous Thromboembolism
-
批准号:6603798
-
项目类别:
-
资助金额:$31.5万
-
财政年份:2002
-
负责人:Robert J Glynn
-
依托单位:
Medication Use, Comorbidity and Outcomes in Older People
-
批准号:6739069
-
项目类别:
-
资助金额:$38.93万
-
财政年份:2002
-
负责人:Robert J Glynn
-
依托单位:
Medication Use, Comorbidity and Outcomes in Older People
-
批准号:6472338
-
项目类别:
-
资助金额:$34.52万
-
财政年份:2002
-
负责人:Robert J Glynn
-
依托单位:
Medication Use, Cormobidity and Outcomes in Aging Populations
-
批准号:7464947
-
项目类别:
-
资助金额:$32.29万
-
财政年份:2002
-
负责人:Robert J Glynn
-
依托单位:
Medication Use, Comorbidity and Outcomes in Aging populations
-
批准号:7317021
-
项目类别:
-
资助金额:$39.38万
-
财政年份:2000
-
负责人:Robert J Glynn
-
依托单位:
SECONDARY PREVENTION TRIAL OF VENOUS THROMBOSIS-DCC
-
批准号:6056409
-
项目类别:
-
资助金额:$23.22万
-
财政年份:1998
-
负责人:Robert J Glynn
-
依托单位:
SECONDARY PREVENTION TRIAL OF VENOUS THROMBOSIS-DCC
-
批准号:6527117
-
项目类别:
-
资助金额:$32.92万
-
财政年份:1998
-
负责人:Robert J Glynn
-
依托单位:
SECONDARY PREVENTION TRIAL OF VENOUS THROMBOSIS-DCC
-
批准号:2605595
-
项目类别:
-
资助金额:$38.76万
-
财政年份:1998
-
负责人:Robert J Glynn
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: